DSM Biologics launches Australian biopharma manufacturing facility

DSM Biologics, a business unit of DSM Pharmaceutical Products, a global business providing cGMP custom manufacturing services across all facets of the pharmaceutical industry, has signed preliminary agreements with the Australian government to design, build and operate the first major Australia-based mammalian biopharmaceutical manufacturing facility, which will be located in Brisbane.

PARSIPPANY, N.J.—DSM Biologics, a business unit of DSMPharmaceutical Products, a global business providing cGMP custom manufacturingservices across all facets of the pharmaceutical industry, has signedpreliminary agreements with the Australian government to design, build andoperate the first major Australia-based mammalian biopharmaceuticalmanufacturing facility, which will be located in Brisbane. DSM Biologics willuse the 70,000-plus square-foot facility to offer mammalian process developmentand cGMP clinical and commercial manufacturing services to Australia andclients from all over the world. Among the services it currently offers aresmall-molecule API and intermediates manufacturing, fill/finish of parenteraland solid dosage forms and large-molecule drug substance production.

 

 

 


Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

February 2023 Front Cover

Latest Issue  

• Volume 19 • Issue 2 • February 2023

February 2023

February 2023 Issue